Compare BVFL & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BVFL | VTVT |
|---|---|---|
| Founded | 1873 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.6M | 148.7M |
| IPO Year | 2023 | 2015 |
| Metric | BVFL | VTVT |
|---|---|---|
| Price | $19.79 | $36.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $53.00 |
| AVG Volume (30 Days) | 7.8K | ★ 45.7K |
| Earning Date | 04-24-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.19 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $151.31 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.05 | $14.00 |
| 52 Week High | $20.54 | $44.00 |
| Indicator | BVFL | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 57.27 |
| Support Level | $19.27 | $34.29 |
| Resistance Level | $19.91 | $41.59 |
| Average True Range (ATR) | 0.44 | 2.23 |
| MACD | -0.04 | 0.77 |
| Stochastic Oscillator | 40.70 | 86.86 |
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.